Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37428659

about

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37428659

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@en

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@nl

type

label

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@en

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@nl

prefLabel

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@en

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@nl

P1433

Q37428659-E50F5248-FCC6-4B3B-AD80-8FA0C2CE59A9

P1476

Q37428659-743C4DF7-C652-4C00-B80B-5A64C4F64C5D

P2093

Q37428659-FFA540D8-49A1-4640-BDE0-CA7BB7837F2B

P2860

Q37428659-01BCBFDB-EB1B-46C6-B6DE-26BDA5CE8E71

Q37428659-07C3033E-70E2-4704-9B2C-D5C271B5870D

Q37428659-088D6813-4F4D-49CB-8A76-44A301BDC552

Q37428659-0DB570E2-4D06-4E4D-8D0C-F1E3C84EC4AA

Q37428659-14A411EF-19A0-4F44-A565-25276D31872C

Q37428659-1533C4E4-CD27-4C3E-AA0A-45BFC109060E

Q37428659-17150323-6A74-4A5F-A845-6429B3349C77

Q37428659-1B3DC739-BB2F-418A-9EE0-2814A5B01720

Q37428659-1DCEDB36-34D3-4413-9503-D5D1E575EC88

Q37428659-2049460B-E428-449B-BD3D-0227C4AE78DB

P304

Q37428659-1634AF61-400C-4AF8-9EA7-3E65C297EAD1

P31

Q37428659-E0EBE4A3-46D8-409C-9ED9-DFFC9B1CA950

P356

Q37428659-E2AF2E6D-A5D0-448E-98CD-96769010BF8A

P433

Q37428659-AC75EE4D-E8EA-4B4F-8969-D16A9F203372

P478

Q37428659-AC9739B3-41A5-4A7C-9097-0968FF7CFD42

P577

Q37428659-386441BB-303B-4918-BEAC-EDE7C7CD2A98

P698

Q37428659-D10B58DD-1277-4C95-9F44-63E7F12FC0AB

P921

Q37428659-2CF74B1A-5B23-46CC-952A-AA6ED19D8083

P356

107327480901600203

P1433

P1476

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

@en

P2093

Michael J Mauro

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Overriding imatinib resistance with a novel ABL kinase inhibitor

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

Gene expression changes associated with progression and response in chronic myeloid leukemia.

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).

P304

108-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107327480901600203

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19337197

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia